Cargando…

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia

OBJECTIVE: An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. MATERIALS AND METHODS: Rivastigmine (uptitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Pattath Narayanan Suresh, Mohemmedali, Seema P., Anish, P. K., Andrade, Chittaranjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547865/ https://www.ncbi.nlm.nih.gov/pubmed/28827871 http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_133_16

Ejemplares similares

Transcranial direct current stimulation for refractory auditory hallucinations in schizophrenia: Acute and 16-week outcomes
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2020)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Arabzadeh, Somaye, et al.
Publicado: (2018)

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial
por: Mortazavi, Mehran, et al.
Publicado: (2015)

RISPERIDONE - INDUCED TARDIVE DYSKINESIA : CASE REPORT AND REVIEW OF LITERATURE
por: Kumar, P.N. Suresh, et al.
Publicado: (2001)

Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia
por: Suresh Kumar, P. N., et al.
Publicado: (2016)

Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial
por: Zandifar, Atefeh, et al.
Publicado: (2022)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial
por: Barnes, Thomas R.E., et al.
Publicado: (2018)

Olanzapine has poorer efficacy than risperidone for the treatment of the negative symptoms of schizophrenia
por: Vadlamani, Laxmi Naresh, et al.
Publicado: (2017)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2011)

Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study
por: Veerman, S. R. T., et al.
Publicado: (2016)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
por: Djordjevic, Snezana, et al.
Publicado: (2010)

Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)

RISPERIDONE AUGMENTATION OF CLOZAPINE
por: Agarwal, Vivek
Publicado: (1999)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia
por: Sagar, K.J. Vijay, et al.
Publicado: (2005)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen
por: Henderson, Emily J, et al.
Publicado: (2013)

Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial
por: Sommer, Iris E, et al.
Publicado: (2021)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders
por: Ghanizadeh, Ahmad, et al.
Publicado: (2013)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial
por: Van Eijk, MM, et al.
Publicado: (2011)

A DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF THE ANXIOLYTIC EFFICACY FF AN ETHANOLIC EXTRACT OF WITHANIA SOMNIFERA
por: Andrade, Chittaranjan, et al.
Publicado: (2000)

Risperidone Versus Risperidone Plus Sodium Valproate for Treatment of Bipolar Disorders: A Randomized, Double-Blind Clinical-Trial
por: Moosavi, S. Mohammad, et al.
Publicado: (2014)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011)

The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial
por: Lee, Jieun, et al.
Publicado: (2011)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Risperidone Associated Paralytic Ileus in Schizophrenia
por: Ramamourthy, Parthasarathy, et al.
Publicado: (2013)

Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study
por: Govani, Viraj, et al.
Publicado: (2023)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial
por: Samadi, Roya, et al.
Publicado: (2017)

Effect of Cuscuta epithymum Acquainted with Risperidone on the Improvement of Clinical Symptoms and Cognitive Impairment in Patients with Schizophrenia: A Triple-Blind Randomized Placebo-Controlled Trial
por: Parvizi, Maedeh, et al.
Publicado: (2019)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
por: Shiina, Akihiro, et al.
Publicado: (2010)

Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
por: Neumann, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pb5m0cb41uthapmd8eih8sh8rc